Chinese officials are expected to be in Washington this week to hold consultations with the U.S. ahead of high-level trade talks in October.World Economyread more
Saudi Arabia's defense spending is the world's third-largest — behind the U.S. and China, says Gary Grappo, former U.S. ambassador to Oman.Energyread more
President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
Valeant Pharmaceuticals on Tuesday decided to take the name of its best performing optical products unit as part of a turnaround plan and raised its 2018 revenue forecast.
Valeant will become Bausch Health Companies from July as Chief Executive Officer Joseph Papa works to restore investor confidence after several investigations into the company's accounting and pricing practices hit its shares.
The company has lost nearly 93 percent of value from its 2015 highs and sold several businesses to pay down debt, which ballooned to more than $30 billion following a spate of deal-making under its previous CEO Mike Pearson.
"It became clear that Bausch Health Companies best represents the company we are today," said Papa in a statement.
The name change reflects the company's optical products business, Bausch and Lomb, which brought in sales of $1.10 billion in the first quarter and accounted for more than half of the company's total revenue.
The company, which would trade under the new ticker symbol "BHC", has reduced its debt by more than 20 percent in the past two years, since Papa took the helm.
U.S.-listed shares of the Canadian drugmaker rose 6.3 percent to $19.3 in trading before the bell.
The company raised its full-year revenue forecast range to $8.15 billion$8.35 billion from $8.10 billion$8.30 billion, partly helped by the performance of its Bausch and Lomb unit.
Net loss attributable to the company was at $2.69 billion, or $7.68 per share, in the quarter ended March 31, compared with a profit of $628 million, or $1.79 per share, a year earlier.
Total revenues fell 5.4 percent to $1.96 billion.
According to Thomson Reuters I/B/E/S, the company earned 88 cents per share, excluding items, beating analysts' average estimate of 60 cents per share.
—Valeant CEO Joe Papa joins Jim Cramer on CNBC's "Mad Money" tonight at 6 p.m. ET.